ArticleCell reports2015
A small-molecule screen for enhanced homing of systemically infused cells.
Article in Cell reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 50 citations in OpenAlex.
- Article
- Mesenchymal stem cells and the central nervous system: historical perspectives and future directions.Frontiers in molecular neuroscience · 2026Review
- Sugar Functionalized Collagen Material for Local Modulation of Innate Immunity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Neurotrophic factors in multiple sclerosis.Frontiers in immunology · 2025Review
- Microengineered In Vitro Assays for Screening and Sorting Manufactured Therapeutic T Cells.Journal of immunology (Baltimore, Md. : 1950) · 2024Review
- Editing a gateway for cell therapy across the blood-brain barrier.Brain : a journal of neurology · 2023Review
- Functional enhancement strategies to potentiate the therapeutic properties of mesenchymal stromal cells for respiratory diseases.Frontiers in pharmacology · 2023Review
- Translating musculoskeletal bioengineering into tissue regeneration therapies.Science translational medicine · 2022Review
- CAR-T Cells/-NK Cells in Cancer Immunotherapy and the Potential of MSC to Enhance Its Efficacy: A Review.Biomedicines · 2022Review
- In-cytoplasm mitochondrial transplantation for mesenchymal stem cells engineering and tissue regeneration.Bioengineering & translational medicine · 2022Article
- Intravenously Infused Stem Cells for Cancer Treatment.Stem cell reviews and reports · 2021Review
- Cell-based drug delivery harnesses inflammatory and autoimmune responses in neurodegeneration.Journal of molecular medicine (Berlin, Germany) · 2021Article
- A cell-based drug delivery platform for treating central nervous system inflammation.Journal of molecular medicine (Berlin, Germany) · 2021Article
- Engineering the MSC Secretome: A Hydrogel Focused Approach.Advanced healthcare materials · 2021Review
- Reversible Growth-Arrest of a Spontaneously-Derived Human MSC-Like Cell Line.International journal of molecular sciences · 2020Article
- Anti-Inflammatory Effects of Magnetically Targeted Mesenchymal Stem Cells on Laser-Induced Skin Injuries in Rats.International journal of nanomedicine · 2020Article
- Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies.Stem cell research & therapy · 2019Review
- A Phase I Study to Assess the Safety and Cancer-Homing Ability of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Men with Localized Prostate Cancer.Stem cells translational medicine · 2019Article
- TAFA2 Induces Skeletal (Stromal) Stem Cell Migration Through Activation of Rac1-p38 Signaling.Stem cells (Dayton, Ohio) · 2019Article
- KIAA1199 is a secreted molecule that enhances osteoblastic stem cell migration and recruitment.Cell death & disease · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 6 institutions in 2 countries.
Funding
Abstract
Poor homing of systemically infused cells to disease sites may limit the success of exogenous cell-based therapy. In this study, we screened 9,000 signal-transduction modulators to identify hits that increase mesenchymal stromal cell (MSC) surface expression of homing ligands that bind to intercellular adhesion molecule 1 (ICAM-1), such as CD11a. Pretreatment of MSCs with Ro-31-8425, an identified hit from this screen, increased MSC firm adhesion to an ICAM-1-coated substrate in vitro and enabled targeted delivery of systemically administered MSCs to inflamed sites in vivo in a CD11a- (and other ICAM-1-binding domains)-dependent manner. This resulted in a heightened anti-inflammatory response. This represents a new strategy for engineering cell homing to enhance therapeutic efficacy and validates CD11a and ICAM-1 as potential targets. Altogether, this multi-step screening process may significantly improve clinical outcomes of cell-based therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.